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a  b  s  t  r  a  c  t
Background:  Delayed-type  hypersensitivity  (DTH)  test  responsiveness  is  associated  with  HIV  disease  pro-
gression; however  it is  unknown  whether  other  immune  markers,  such  as  hepatitis  B  virus (HBV)  vaccine
seroresponse,  also predict  HIV outcomes.
Methods:  Eligible  participants  received  HBV  vaccine  after  HIV  diagnosis,  had  non-anergic  DTH  testing
at  the  time  of  last  HBV  vaccination,  and  available  post-vaccine  HBV  antibody  responses.  The risk  of
progression  to AIDS  or  death from  the  time  of  last  HBV  vaccination  was  evaluated.
Results: Of  369  eligible  participants  with non-anergic  DTH  responses,  148 (40%)  were  HBV  vaccine  respon-
ders.  In  a multivariate  model  adjusted  for age, CD4  count,  viral  load,  and  number  of vaccinations,  HBV
vaccine non-responders  had  an  increased  risk  of  progression  to  AIDS  or  death  (HR  1.81;  95%  CI,  1.03–3.19).
Conclusions:  HBV  vaccine  seroresponses  were  independent  of  DTH  responses  which  suggest  that  non-
response  to HBV  vaccine  is not  solely  due  to  cell-mediated  immune  dysfunction  in HIV-infected  persons.
Published  by  Elsevier  Ltd.
1. Introduction
The natural history of HIV infection results in a progressive
decline in immune function and, if untreated, ultimately leads
to the development of Acquired Immunodeficiency Syndrome
(AIDS) and death. The advent of potent, well-tolerated antiretro-
viral therapy (ART) has significantly improved life expectancy in
HIV-infected patients [1]. Despite the successes of modern ART
regimens, both AIDS and serious non-AIDS events can occur, even at
relatively preserved CD4 cell counts [2–4]. In addition to measure-
ment of CD4 counts, other clinically relevant immune correlates
are necessary to better understand HIV pathogenesis and predict
disease progression.
Delayed-type hypersensitivity (DTH) testing is a tool that can
be used to evaluate cell-mediated immunity (CMI) in clinical sett-
ings [5]. Cutaneous anergy to recall antigens is a predictor of HIV
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disease progression independent of viral load (VL) and CD4 count
[6,7]. Whether markers for other aspects of immune function also
predict HIV outcomes over and above DTH has not been com-
pletely studied. We  previously demonstrated that hepatitis B virus
(HBV) vaccine responsiveness can also be used to predict future
AIDS events or death [8]. Although HBV vaccine is a T-cell depend-
ent antigen, a positive seroresponse to HBV vaccine requires other
aspects of immune function including antigen presentation of the
peptide-based vaccine as well as B-cell activity [9–11]. We  eval-
uated the relationships between the humoral response to HBV
vaccine, CMI  by DTH responses, and progression to clinical AIDS
and death in the U.S. Military HIV Natural History Study (NHS).
2. Methods
The NHS is a prospective observational cohort comprised of
more than 5500 military members, dependents, and beneficiaries
with HIV-1 infection that are followed at 7 military medical treat-
ment facilities in the U.S. since 1986. Participants enrolled were
age 18 or older and provided signed, written consent in this IRB-
approved study and are evaluated approximately every 6 months.
http://dx.doi.org/10.1016/j.vaccine.2014.04.049
0264-410X/Published by Elsevier Ltd.
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Table 1
Characteristics of participants with non-anergic DTH test results at the time of last HBV vaccination by vaccine response category.
Characteristic N Anti-HBs < 10 IU/LN = 221 Anti-HBs ≥ 10 IU/LN = 148 P
Age (years) 369 31 (27–36) 31 (26–37) 0.76
Gender, male 369 202 (91) 124 (84) 0.03
Ethnicity 369 0.85
Caucasian 96 (43) 59 (40)
African American 98 (44) 66 (45)
Other  27 (12) 23 (16)
CD4  count (cells/L) 360 451 (318–613) 573 (418–737) <0.001
CD4  count category (cells/L) 360 <0.001
<200  23 (10) 6 (4)
200–499 103 (47) 49 (33)
≥500  90 (41) 89 (60)
HIV  VL (log10 copies/mL) 231 3.33 (2.30–4.38) 2.30 (2.21–3.85) <0.001
HIV  VL category (copies/mL) 369 <0.001
≤400 37 (17) 46 (31)
>400  85 (38) 63 (43)
Unknown 99 (45) 39 (26)
Number of vaccinations 369 0.09
1–2 102 (46) 55 (37)
≥3  119 (54) 93 (63)
On  ART at vaccination 369 182 (82) 102 (69) <0.01
Year  of vaccination 369 <0.001
<1996 134 (61) 58 (39)
≥1996 87 (39) 90 (61)
Follow-up (years) 369 5.4 (2.5–10.1) 6.7 (3.0–11.2) 0.16
Total  (patient-years) 1463 1071
Total  number of AIDS or death events 369 68 17 <0.001
DTH, delayed-type hypersensitivity; HBV, hepatitis B virus; anti-HBs, antibody to HBV surface antigen; VL, viral load; ART, antiretroviral therapy.
Data  are number (%) or median (interquartile range) unless otherwise specified.
In this retrospective study, participants were required to be
HBV vaccine naïve prior to their HIV diagnosis with no history of
HBV infection. Participants were also required to have received
at least one dose of HBV vaccine and have DTH testing results
at the time of last vaccination. Participants were classified as
either vaccine responders or non-responders based on antibody
to HBV surface antigen (anti-HBs) ≥10 or <10 IU/L, respectively.
Since anti-HBs can wane ≥2 years after vaccination in HIV-infected
adults [12], only participants with measured anti-HBs between
1 and 12 months after last vaccination were included to pre-
vent misclassification. DTH testing was performed according to
standardized NHS protocols as previously described [6,13,14]. A
total of 0.1 mL  of each antigen was applied intradermally to the
forearm by Mantoux method and a positive test was defined as
≥5 mm of induration after 48 h. The most recent antigens and
concentrations used per protocol consisted of tetanus toxoid (Led-
erle 1.6 Lf/mL; 1:100 dilution), mumps  (Connaught, 40 CFU/mL),
trichophyton (Holister-Stier, 1:500 dilution), and candida (Wal-
ter Reed Army Institute of Research, 200 PNU/mL). Participants
received a panel of 3–4 antigens, with the majority receiving 3
antigens as trichophyton was removed from the market. DTH
responses were categorized by the number of positive skin tests:
anergic (0), partial anergic (1), or non-anergic (≥2) as previously
described [13]. The subgroup with non-anergic DTH responses was
further studied for clinical outcomes based on HBV vaccine serore-
sponse.
HBV vaccine non-responder and responder characteristics were
compared by chi-squared or Fisher’s Exact tests. AIDS outcomes
were defined by 1993 Centers for Disease Control and Prevention
criteria, with the exception of CD4 count [15]. Vaccine responders
were followed from the time of their last HBV vaccination to the
development of AIDS, death, or last study visit. Risk of progression
for the combined endpoint of AIDS or death from the time of last
HBV vaccination was evaluated with multivariate Cox regression
and time to AIDS or death was assessed by Kaplan–Meier survival
methods.
3. Results
A total of 507 NHS participants vaccinated from 1986 to 2005
met  inclusion criteria, of which 65 (12.8%) had anergic DTH
responses, 73 (14.4%) had partially anergic DTH responses, and 369
(72.8%) had non-anergic DTH responses. The proportion with a pos-
itive HBV vaccine response did not differ by DTH category: 31%,
30%, and 40% for anergic, partially anergic, and non-anergic, respec-
tively (P = 0.13). Participants with non-anergic DTH responses were
further investigated for HIV disease progression based on HBV
vaccine seroresponse after last vaccination (Table 1). A greater pro-
portion of participants were classified as non-responders (59.9%)
compared to responders (40.1%), but demographic characteristics
including age, gender, and race/ethnicity were similar between
subgroups. Most participants in both groups were treated with
ART at time of last vaccination and received ≥3 vaccine doses. At
the time of last HBV vaccination, the median CD4 count and VL
for non-responders compared to responders was 451 cells/L (IQR
318–613) versus 573 cells/L (IQR 418–737; P < 0.001) and 3.33
versus 2.30 log10 copies/mL, respectively (P < 0.001 for both). VL at
last vaccination was unavailable for 138 (37.4%) of study partici-
pants since clinical VL assessments were not routinely performed
prior to 1996.
Participants were followed for a median of 5.4 years (IQR
2.5–10.1) in the non-responder group and 6.7 years (IQR 3.0–11.2)
in the responder group for a total of 1463 and 1071 person-
years, respectively (P = 0.16). In participants with non-anergic DTH
responses, 85 (23%) progressed to AIDS or death, including occur-
rence in 68 (31%) HBV vaccine non-responders and 17 (11%)
responders (P < 0.001). In preliminary models, gender, year of vac-
cination, and receiving ART at vaccination were not significantly
associated with AIDS or death risk. The risk of progression to AIDS
or death for HBV vaccine non-responders and responders was
assessed by multivariate analysis adjusted for age, CD4 cell count,
HIV VL, and number of vaccine doses (Table 2). HBV vaccine non-
responders were found to have an increased risk of progression to
S.B. Patterson et al. / Vaccine 32 (2014) 3341–3344 3343
Table  2
Final age-adjusted multivariate model for risk of progression to AIDS or death among
those with non-anergic DTH test results.
Characteristic HR (95% CI) P
CD4 count category (cells/L)
<200 9.10 (4.66–17.75) <0.001
200–499 2.11 (1.20–3.71) 0.01
≥500 Referent
HIV VL category (copies/mL)
≤400 0.13 (0.03–0.55) <0.01
>400 0.66 (0.33–1.35) 0.26
Unknown Referent
Number of vaccinations
1–2 1.70 (1.07–2.69) 0.02
≥3  Referent
HBV vaccine response
Anti-HBs <10 IU/L 1.81 (1.03–3.19) 0.04
Anti-HBs ≥10 IU/L Referent
DTH, delayed-type hypersensitivity; HR, hazard ratio; CI, confidence interval; VL,
viral load; HBV, hepatitis B virus; anti-HBs, antibody to HBV surface antigen.
Gender, year of vaccination, and receiving ART at vaccination, were all not signifi-
cantly associated with AIDS or death risk in preliminary models.
AIDS or death (HR, 1.81; 95% CI, 1.03–3.19). The time to AIDS or
death was significantly greater for HBV vaccine responders com-
pared to non-responders (Fig. 1; P < .001).
4. Discussion
In a large cohort of HIV-infected adults, we found that most
participants with non-anergic DTH responses to recall antigens
did not demonstrate protective seroresponses to HBV vaccine. We
also observed that HBV vaccine response status was a predictor
of subsequent AIDS or death among those with non-anergic DTH
responses. These findings suggest that non-response to HBV vac-
cine is not entirely due to CMI  dysfunction in individuals infected
with HIV, but other immune deficits likely contribute to the lack of
anti-HBs response after vaccination.
As an in vivo marker of CMI, DTH responsiveness is enhanced
at higher CD4 cell counts. For example, one study showed that
responses to 2 or more recall antigens was 86% for those with
CD4 >400 cells/L compared to only 45% for those <400 cells/L
[10]. However, DTH responsiveness has also been shown to be a
predictor of HIV disease progression in untreated individuals inde-
pendent of CD4 cell count [6,7,16]. A previous study in our cohort
showed that the total number of reactive skin tests (0, 1, or 2–4)
Fig. 1. Time to AIDS or death for those with non-anergic DTH test results by HBV
vaccine response (P < 0.001 by log rank).
stratified patients according to survival time and progression to
AIDS [13]. In the current study, we observed that in HIV-infected
patients with non-anergic DTH responses, a marker for more favor-
able CMI, seroresponses to HBV vaccine also had prognostic value.
Although DTH testing has long been used in clinical practice for var-
ious purposes, such as screening for latent tuberculosis infection,
DTH methods are not routinely used in HIV medicine. HBV vaccine
seroresponses may  be of greater practical use since HBV vaccine
is recommended for all HIV-infected persons and anti-HBs, a val-
idated marker for HBV vaccine response, is routinely measured in
clinical practice [17,18].
HBV vaccine response, a surrogate for humoral immune func-
tion, may  be used in a similar manner as DTH response to help
identify other host or viral factors that influence HIV disease course
and potential response to specific therapies. The effect of HIV on
CMI has been utilized in several prediction models to assess the
severity of disease and response to therapy by evaluating CD4 cell
count, total lymphocyte count, T-cell subtypes, and DTH response
in addition to viral load as independent risk factors [8,13,14,19–21].
In a previous study in our cohort, a greater likelihood of HBV vaccine
response was  demonstrated in those with higher CD4 cell counts at
last vaccination, use of ART, and receipt of ≥3 doses of HBV vaccine
[21]. HBV vaccine seroresponse was  also associated with progres-
sion to AIDS or death, even in those with CD4 counts >500 cells/L.
Since DTH responsiveness is improved at higher CD4 counts, the
observation in the current study that HBV vaccine seroresponse
remains predictive of HIV disease progression in those with non-
anergic DTH testing is consistent with prior findings. Although
HBV vaccine is a T-cell dependent antigen, only 40% of HBV vac-
cine responders were non-anergic by DTH testing which suggests
that additional immune factors contribute to the development of
anti-HBs response.
As future efforts continue to shed new light on the immunologic
relationships in the pathogenesis and progression of HIV infection,
HBV vaccine seroresponses may  serve as a useful tool for predict-
ing HIV disease progression in addition to other clinical laboratory
makers such as CD4 count and VL. Identification of additional fac-
tors that affect the innate and adaptive immune components could
help tailor treatments, guide future therapies, and provide addi-
tional data to predict the course of disease for individuals infected
with HIV.
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